The above discussion has provided an overview of the use of animal models that my laboratory has adapted to study immunoregulation in two discrete models of malignancy, namely CLL and breast cancer, and the role played by the CD200:CD200R axis in that regulation. This evidence concerns the gene CD200 and B-cell chronic lymphocytic leukemia.